摘要
目前已批准了五种程序性死亡-1 /程序性死亡配体1(PD-L1)抑制剂用于治疗膀胱和上尿路的局部晚期或转移性尿路上皮癌。 FDA和EMA限制不适合铂类患者使用Atezolizumab和Pembrolizumab一线治疗的限制后,现在需要进行免疫组织化学PD-L1检测。 关于抗体,测试平台和评分算法的一些新出现的问题引起了人们对这些试验之间可比性和互换性的担忧。 在这篇综述中,我们集中于尿路上皮癌PD-L1检测所用算法和测定法的互换性,尿路上皮癌PD-L1检测的预测可靠性以及其他新的和即将出现的生物标记物的潜力。
关键词: PD-L1,免疫组化,尿路上皮癌,生物标志物,互换性,免疫疗法。
图形摘要
Current Drug Targets
Title:PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
Volume: 22 Issue: 2
关键词: PD-L1,免疫组化,尿路上皮癌,生物标志物,互换性,免疫疗法。
摘要: Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients, immunohistochemical PD-L1 testing is now required. Several emerging issues on antibodies, test platforms and scoring algorithms have raised concerns about the comparability and interchangeability between these assays. In this review, we have focused on the interchangeability of the used algorithms and assays for PD-L1 testing in urothelial carcinoma, on the predictive reliability of PD-L1 testing in urothelial carcinoma and the potential of other new and upcoming biomarkers.
Export Options
About this article
Cite this article as:
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives, Current Drug Targets 2021; 22 (2) . https://dx.doi.org/10.2174/1389450121666200510015216
DOI https://dx.doi.org/10.2174/1389450121666200510015216 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy
Current Medicinal Chemistry Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy A Quantitative Proteomics Approach in the Study of MicroRNA 181a in HepG2 Cells
Current Proteomics TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Withdrawal Notice: Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Current Drug Targets Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design